# US 2018/0021426 A1 · Combination Purified Inactivated Vaccine for Flaviviruses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021426 A1
- Document ID: US20180021426A1
- Status: Published application
- Kind: A1
- Application number: 15/550,433
- Filed: 2016-03-10
- Published: 2018-01-25
- Earliest claimed: 2015-03-11
- Assignees: The United States of America, as represented by the Secretary, on behalf of the Walter Reed Army
- Applicants: The United States of America, as represented by the Secretary, on behalf of the Walter Reed Army
- Inventors: Stephen J. Thomas; Kenneth H. Eckels; Joseph R. Putnak
- Web page: https://patentgrep.com/patent/US20180021426A1

## CPC

- A61K 39/12: Viral antigens
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/70: {Multivalent vaccine}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 2770/24034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24051: Methods of production or purification of viral material
- C12N 2770/24134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/24151: Methods of production or purification of viral material
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Disclosed herein are immunogenic compositions comprising one or more inactivated dengue viruses and one or more inactivated non-dengue flaviviruses and methods of making and using thereof.

## Claims

### Claim 1

An immunogenic composition comprising one or more inactivated dengue viruses and one or more inactivated non-dengue flaviviruses and a pharmaceutically acceptable vehicle.

### Claim 2 (depends on 1)

The immunogenic composition of claim 1, wherein the one or more inactivated dengue viruses are selected from the group consisting of an inactivated DENV-1, an inactivated DENV-2, an inactivated DENV-3, and an inactivated DENV-4.

### Claim 3 (depends on 1)

The immunogenic composition of claim 1, wherein the one or more inactivated dengue viruses consist of an inactivated DENV-1, an inactivated DENV-2, an inactivated DENV-3, and an inactivated DENV-4.

### Claim 4 (depends on 1)

The immunogenic composition according to claim 1, wherein said dengue virus is an inactivated DENV-1 produced from deposited DENV-1 strain having ATCC accession number VR-2649.

### Claim 5 (depends on 1)

The immunogenic composition according to claim 1, wherein said dengue virus is an inactivated DENV-2 produced from deposited DENV-2 strain having ATCC accession number VR-2650.

### Claim 6 (depends on 1)

The immunogenic composition according to claim 1, wherein said dengue virus is an inactivated DENV-3 produced from deposited DENV-3 strain having ATCC accession number VR-2654.

### Claim 7 (depends on 1)

The immunogenic composition according to claim 1, wherein said dengue virus is an inactivated DENV-4 produced from deposited DENV-4 strain having ATCC accession number VR-2651.

### Claim 8 (depends on 1)

The immunogenic composition according to claim 1, wherein the one or more inactivated non-dengue flaviviruses are selected from the group consisting of yellow fever group viruses and Japanese encephalitis group viruses.

### Claim 9 (depends on 1)

The immunogenic composition according to claim 1, wherein the one or more inactivated non-dengue flaviviruses are selected from the group consisting of yellow fever virus (YFV), Japanese encephalitis virus (JEV), and West Nile virus (WNV).

### Claim 10 (depends on 1)

The immunogenic composition according to claim 1, wherein the one or more inactivated non-dengue flaviviruses are yellow fever virus (YFV) and Japanese encephalitis virus (JEV).

### Claim 11 (depends on 1)

The immunogenic composition according to claim 1, wherein the one or more inactivated non-dengue flavivirus is Zika virus (ZIKV).

### Claim 12 (depends on 1)

The immunogenic composition according to claim 1, wherein the one or more inactivated dengue viruses are present in an immunologically effective amount and/or the one or more inactivated non-dengue flaviviruses are present in an immunologically effective amount.

### Claim 13 (depends on 1)

The immunogenic composition according claim 1, wherein the one or more inactivated dengue viruses are purified and/or the one or more inactivated non-dengue flaviviruses are purified.

### Claim 14 (depends on 1)

The immunogenic composition according to claim 1, and further comprising an adjuvant.

### Claim 15 (depends on 1)

A method of producing antibodies against a dengue virus and a non-dengue flavivirus in a subject, which comprises administering to the subject the immunogenic composition according to claim 1.

### Claim 16 (depends on 15)

The method according to claim 15, wherein the immunogenic composition is administered as a single dose on a 0-28 day vaccination schedule.

### Claim 17 (depends on 15)

The method according to claim 15, wherein the administration is by intramuscular injection.

### Claim 18 (depends on 1)

A medicament for producing antibodies against a dengue virus and a non-dengue flavivirus in a subject, which comprises the immunogenic composition according to claim 1.

### Claim 19 (depends on 1)

A method of inducing an immune response in a subject, which comprises administering the immunogenic composition according to claim 1 to the subject.
